The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Cancer evolution: Darwin and beyond
Open accessAbstract
Clinical and laboratory studies over recent decades have established branched evolution as a feature of cancer. However, while grounded in somatic selection, several lines of evidence suggest a Darwinian model alone is insufficient to fully explain cancer evolution. First, the role of macroevolutionary events in tumour initiation and progression contradicts Darwin's central thesis of gradualism. Whole-genome doubling, chromosomal chromoplexy and chromothripsis represent examples of single catastrophic events which can drive tumour evolution. Second, neutral evolution can play a role in some tumours, indicating that selection is not always driving evolution. Third, increasing appreciation of the role of the ageing soma has led to recent generalised theories of age-dependent carcinogenesis. Here, we review these concepts and others, which collectively argue for a model of cancer evolution which extends beyond Darwin. We also highlight clinical opportunities which can be grasped through targeting cancer vulnerabilities arising from non-Darwinian patterns of evolution.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774 · cited 3×
“…next-generation sequencing (NGS), that the full breath of ITH could start to be fully resolved (Campbell et al , 2010 ; Navin et al , 2010 ; Gerlinger et al , 2012 ; Nik-Zainal et al , 2012 b; Walter et al , 2012 ; Patel et al , 2014 ; Sottoriva et al , 2015 ; Jamal-Hanjani et al , 2017 ;…”
Self-citationNowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, H., Cahill, D. P., Nahed, B. V., Curry, W. T., Martuza, R. L., et al. (2014) · Science · doi:10.1126/science.1254257 · Cited by 5,063 · cited 1×
“…start to be fully resolved (Campbell et al , 2010 ; Navin et al , 2010 ; Gerlinger et al , 2012 ; Nik-Zainal et al , 2012 b; Walter et al , 2012 ; Patel et al , 2014 ; Sottoriva et al , 2015 ; Jamal-Hanjani et al , 2017 ; Naxerova et al , 2017 ; Turajlic et al , 2018 ; Fittall & Van Loo, 2019 ;…”
Nieto, M. A., Huang, R. Y.-J., Jackson, R. A., & Thiery, J. P. (2016) · Cell · doi:10.1016/j.cell.2016.06.028 · Cited by 4,492
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154
Tumour heterogeneity and resistance to cancer therapies
Dagogo-Jack, I., & Shaw, A. T. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.166 · Cited by 3,846
Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial
de Koning, H. J., van der Aalst, C. M., de Jong, P. A., Scholten, E. T., Nackaerts, K., Heuvelmans, M. A., Lammers, J.-W. J., Weenink, C., Yousaf-Khan, U., Horeweg, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911793 · Cited by 3,624
Greaves, M., & Maley, C. C. (2012) · Nature · doi:10.1038/nature10762 · Cited by 3,162
Detection and localization of surgically resectable cancers with a multi-analyte blood test
Cohen, J. D., Li, L., Wang, Y., Thoburn, C., Afsari, B., Danilova, L., Douville, C., Javed, A. A., Wong, F., Mattox, A., et al. (2018) · Science · doi:10.1126/science.aar3247 · Cited by 2,783
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Tumour evolution inferred by single-cell sequencing
Navin, N., Kendall, J., Troge, J., Andrews, P., Rodgers, L., McIndoo, J., Cook, K., Stepansky, A., Levy, D., Esposito, D., et al. (2011) · Nature · doi:10.1038/nature09807 · Cited by 2,598
The mutational landscape of lethal castration-resistant prostate cancer
Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., et al. (2012) · Nature · doi:10.1038/nature11125 · Cited by 2,517 · cited 1×
“Third, these samples can be used for the development of patient-derived xenografts, organoids and primary cell lines, thus allowing mechanisti-cal validation of the data generated through orthogonal analyses (Grasso et al , 2012 ; Xie et al , 2015 ; Krook et al , 2019 b).”
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R. H., Eshleman, J. R., Nowak, M. A., et al. (2010) · Nature · doi:10.1038/nature09515 · Cited by 2,502
Massive genomic rearrangement acquired in a single catastrophic event during cancer development
Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., Pleasance, E. D., Lau, K. W., Beare, D., Stebbings, L. A., et al. (2011) · Cell · doi:10.1016/j.cell.2010.11.055 · Cited by 2,414 · cited 7×
“Specifically, increasing evidence now supports macroevolutionary jumps as a feature of cancer (Stephens et al , 2011; Baca et al , 2013; Sottoriva et al , 2015), which are likely interspaced by phases of microevolutionary gradualism.”
InfluentialTracking the Evolution of Non–Small-Cell Lung Cancer
Jamal-Hanjani, M., Wilson, G. A., McGranahan, N., Birkbak, N. J., Watkins, T. B. K., Veeriah, S., Shafi, S., Johnson, D. H., Mitter, R., Rosenthal, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616288 · Cited by 2,349
Self-citationAnalysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Dawson, S.-J., Tsui, D. W. Y., Murtaza, M., Biggs, H., Rueda, O. M., Chin, S.-F., Dunning, M. J., Gale, D., Forshew, T., Mahler-Araujo, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213261 · Cited by 2,207 · cited 1×
“Growing evidence supports the feasibility of blood-based tests to monitor tumour evolution across several tumour types (Misale et al , 2012 ; Dawson et al , 2013 ; Aceto et al , 2014 ; Scher et al , 2015 ; Sira-vegna et al , 2015 ; Abbosh et al , 2017 , 2018 ; Anagnostou et al , 2019 ; Vidal et al…”
A cytokine-mediated link between innate immunity, inflammation, and cancer
Lin, W.-W., & Karin, M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31537 · Cited by 1,940 · cited 1×
“…et al , 2016; Wu et al , 2016), cell plasticity (Pogrebniak & Curtis, 2018; Mills et al , 2019; Boumahdi & de Sauvage, 2020) and the tumour microenvironment (Coussens & Werb, 2002; Lin & Karin, 2007; Laconi et al , 2020) in cancer demand consideration of a broader set of evolutionary models.”
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889 · cited 1×
“Growing evidence supports the feasibility of blood-based tests to monitor tumour evolution across several tumour types (Misale et al , 2012 ; Dawson et al , 2013 ; Aceto et al , 2014 ; Scher et al , 2015 ; Sira-vegna et al , 2015 ; Abbosh et al , 2017 , 2018 ; Anagnostou et al , 2019 ; Vidal et al…”
High burden and pervasive positive selection of somatic mutations in normal human skin
Martincorena, I., Roshan, A., Gerstung, M., Ellis, P., Van Loo, P., McLaren, S., Wedge, D. C., Fullam, A., Alexandrov, L. B., Tubio, J. M., et al. (2015) · Science · doi:10.1126/science.aaa6806 · Cited by 1,770 · cited 1×
“…that healthy tissues often display pervasive somatic mutations, even in cancer driver genes, suggests that genetic mechanisms alone may be not be sufficient to drive malignant transformation (Martincorena et al , 2015, 2018; Teixeira et al , 2019; Yizhak et al , 2019; Yoshida et al , 2020).”
Liu, M. C., Oxnard, G. R., Klein, E. A., Swanton, C., Seiden, M. V., Liu, M. C., Oxnard, G. R., Klein, E. A., Smith, D., Richards, D., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.02.011 · Cited by 1,495 · cited 1×
“…these studies still provide accumulating evidence that tumour initiation likely dates back years or even decades before clinical presentation, hence suggesting an extended window for cancer early detection, likely through the use of non-invasive blood-based tests (see Box 3) (Liu et al , 2020).”
Self-citationTie, J., Wang, Y., Tomasetti, C., Li, L., Springer, S., Kinde, I., Silliman, N., Tacey, M., Wong, H.-L., Christie, M., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6219 · Cited by 1,492 · cited 1×
“…to be successful in several studies in bladder cancer (Dudley et al , 2019), NSCLC (Abbosh et al , 2017; Chaudhuri et al , 2017), colon cancer (Tie et al , 2016), breast cancer (Mounier et al , 2015), oesophageal cancer (Azad et al , 2020) and a range of other solid tumour types (Chin et al ,…”
The Life History of 21 Breast Cancers
Nik-Zainal, S., Van Loo, P., Wedge, D. C., Alexandrov, L. B., Greenman, C. D., Lau, K. W., Raine, K., Jones, D., Marshall, J., Ramakrishna, M., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.023 · Cited by 1,443 · cited 3×
“This report was followed by work from Nik-Zainal et al (2012b), who studied the life history of 21 breast tumours, identifying extensive genetic variation within individual breast tumours (Nik-Zainal et al , 2012b).”
The patterns and dynamics of genomic instability in metastatic pancreatic cancer
Campbell, P. J., Yachida, S., Mudie, L. J., Stephens, P. J., Pleasance, E. D., Stebbings, L. A., Morsberger, L. A., Latimer, C., McLaren, S., Lin, M.-L., et al. (2010) · Nature · doi:10.1038/nature09460 · Cited by 1,317 · cited 4×
“…technological innovations (see Box 2 ), particularly next-generation sequencing (NGS), that the full breath of ITH could start to be fully resolved (Campbell et al , 2010 ; Navin et al , 2010 ; Gerlinger et al , 2012 ; Nik-Zainal et al , 2012 b; Walter et al , 2012 ; Patel et al , 2014 ; Sottoriva…”
InfluentialRare cell variability and drug-induced reprogramming as a mode of cancer drug resistance
Shaffer, S. M., Dunagin, M. C., Torborg, S. R., Torre, E. A., Emert, B., Krepler, C., Beqiri, M., Sproesser, K., Brafford, P. A., Xiao, M., et al. (2017) · Nature · doi:10.1038/nature22794 · Cited by 1,218 · cited 1×
“…can therefore enable the emergence of more permanent resistance mechanisms, as was shown in melanoma, whereby therapeutic pressure initially caused the emergence of a transient drug-tolerant transcriptional state which was later converted into a stably resistant phenotype (Shaffer et al , 2017).”
Liquid biopsy enters the clinic — implementation issues and future challenges
Ignatiadis, M., Sledge, G. W., & Jeffrey, S. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00457-x · Cited by 1,191 · cited 1×
“…as circulating tumour cells (CTCs), as well as tumour-derived components such as circulating tumour DNA (ctDNA), cell-free RNAs, extracellular vesicles (EVs), proteins and metabolites (Ramalingam & Jeffrey, 2018 ; Rossi & Ignatiadis, 2019 ; Ignatiadis et al , 2021 ), in patients ’ bodily fluids.”
Spatial and temporal diversity in genomic instability processes defines lung cancer evolution
de Bruin, E. C., McGranahan, N., Mitter, R., Salm, M., Wedge, D. C., Yates, L., Jamal-Hanjani, M., Shafi, S., Murugaesu, N., Rowan, A. J., et al. (2014) · Science · doi:10.1126/science.1253462 · Cited by 1,117 · cited 2×
“In another case, analysis of early NSCLC revealed WGD events and truncal driver events in ex-smokers dating back more than 20 years prior to tumour detection, indicating a prolonged tumour latency period from the first oncogenic insults to clinical manifestation (De Bruin et al , 2014).”
Self-citationSomatic mutant clones colonize the human esophagus with age
Martincorena, I., Fowler, J. C., Wabik, A., Lawson, A. R. J., Abascal, F., Hall, M. W. J., Cagan, A., Murai, K., Mahbubani, K., Stratton, M. R., et al. (2018) · Science · doi:10.1126/science.aau3879 · Cited by 1,113
Liquid biopsy and minimal residual disease - latest advances and implications for cure
Pantel, K., & Alix-Panabières, C. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0187-3 · Cited by 1,110
Biological and therapeutic impact of intratumor heterogeneity in cancer evolution
McGranahan, N., & Swanton, C. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.12.001 · Cited by 1,077
Self-citationClonal evolution in breast cancer revealed by single nucleus genome sequencing
Wang, Y., Waters, J., Leung, M. L., Unruh, A., Roh, W., Shi, X., Chen, K., Scheet, P., Vattathil, S., Liang, H., et al. (2014) · Nature · doi:10.1038/nature13600 · Cited by 1,029
Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Shi, H., Hugo, W., Kong, X., Hong, A., Koya, R. C., Moriceau, G., Chodon, T., Guo, R., Johnson, D. B., Dahlman, K. B., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0642 · Cited by 982
Intratumor Heterogeneity: Evolution through Space and Time
Swanton, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2217 · Cited by 931
Self-citationA renewed model of pancreatic cancer evolution based on genomic rearrangement patterns
Notta, F., Chan-Seng-Yue, M., Lemire, M., Li, Y., Wilson, G. W., Connor, A. A., Denroche, R. E., Liang, S.-B., Brown, A. M. K., Kim, J. C., et al. (2016) · Nature · doi:10.1038/nature19823 · Cited by 528
RNA sequence analysis reveals macroscopic somatic clonal expansion across normal tissues
Yizhak, K., Aguet, F., Kim, J., Hess, J. M., Kübler, K., Grimsby, J., Frazer, R., Zhang, H., Haradhvala, N. J., Rosebrock, D., et al. (2019) · Science · doi:10.1126/science.aaw0726 · Cited by 500
Mechanisms generating cancer genome complexity from a single cell division error
Umbreit, N. T., Zhang, C.-Z., Lynch, L. D., Blaine, L. J., Cheng, A. M., Tourdot, R., Sun, L., Almubarak, H. F., Judge, K., Mitchell, T. J., et al. (2020) · Science · doi:10.1126/science.aba0712 · Cited by 439 · cited 1×
“Similarly, BFB cycles have been shown to generate increasing amounts of chromothripsis by providing free DNA ends that can engage in genomic rearrangement and by compromising centromere function (Umbreit et al , 2020).”
Adaptive mutability of colorectal cancers in response to targeted therapies
Russo, M., Crisafulli, G., Sogari, A., Reilly, N. M., Arena, S., Lamba, S., Bartolini, A., Amodio, V., Magrì, A., Novara, L., et al. (2019) · Science · doi:10.1126/science.aav4474 · Cited by 433 · cited 2×
“…findings were reported in colon cancer, whereby drug-tolerant cells were shown to temporarily down-regulate mismatch repair (MMR) and homologous recombination DNA repair genes in favour of error-prone polymerases as an adaptive response to overcome BRAF and EGFR inhibition (Russo et al , 2019).”
Makohon-Moore, A. P., Zhang, M., Reiter, J. G., Bozic, I., Allen, B., Kundu, D., Chatterjee, K., Wong, F., Jiao, Y., Kohutek, Z. A., et al. (2017) · Nature Genetics · doi:10.1038/ng.3764 · Cited by 403 · cited 1×
“Clear examples of this are described in pancreatic cancer, where virtually all major driver gene alterations ( KRAS, CDKN2A, TP53, SMAD4 ) are present in the most recent common ancestor and limited evidence of mutational heterogeneity is observed across metastases (Makohon-Moore et al , 2017).”
Cancer as a disease of old age: changing mutational and microenvironmental landscapes
Laconi, E., Marongiu, F., & DeGregori, J. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0721-1 · Cited by 348 · cited 3×
“…the accumulation of alterations but also (if not predominantly) because of the age-dependent physiological decline of the soma, combined with a general weakening of the immune system which is less efficient at eliminating altered (precancerous) cells (DeGregori et al , 2020; Laconi et al , 2020).”
Integrating evolutionary dynamics into cancer therapy
Gatenby, R. A., & Brown, J. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0411-1 · Cited by 227 · cited 1×
“However, despite the significant benefits brought about by these approaches, many advanced tumours — even those with marked initial responses — rapidly develop resistance (Gatenby & Brown, 2020).”
Phenotype Switching: Tumor Cell Plasticity as a Resistance Mechanism and Target for Therapy
Kemper, K., de Goeje, P. L., Peeper, D. S., & van Amerongen, R. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1174 · Cited by 216 · cited 2×
“Importantly, although resistant phenotypes are often non-heritable, they can protect the tumour cell population from eradication thereby increasing overall tumour fitness through non-Darwinian mechanisms (Kemper et al , 2014; Gunnarsson et al , 2020; Marine et al , 2020).”
Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA)
Chin, R.-I., Chen, K., Usmani, A., Chua, C., Harris, P. K., Binkley, M. S., Azad, T. D., Dudley, J. C., & Chaudhuri, A. A. (2019) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00390-5 · Cited by 191 · cited 3×
“Small-molecule inhibitors, such as BRAF and EGFR inhibitors (Bedard et al , 2020), and immune checkpoint inhibitors (CPI), such as anti-PD-1/L1 and anti-CTLA-4 (Waldman et al , 2020), have revolutionised cancer therapy (Chen et al , 2019).”
Invasion, establishment, and range expansion of two parasitic nematodes in the Canadian Arctic
Kutz, S. J., Checkley, S., Verocai, G. G., Dumond, M., Hoberg, E. P., Peacock, R., Wu, J. P., Orsel, K., Seegers, K., Warren, A. L., et al. (2013) · Global Change Biology · doi:10.1111/gcb.12315 · Cited by 102 · cited 1×
“For instance, a permissive environment was shown to have led to the expansion of two species of parasites in the Arctic as a consequence of climate change (Kutz et al , 2013; Kafle et al , 2020).”
Bexarotene-Activated Retinoid X Receptors Regulate Neuronal Differentiation and Dendritic Complexity
Mounier, A., Georgiev, D., Nam, K. N., Fitz, N. F., Castranio, E. L., Wolfe, C. M., Cronican, A. A., Schug, J., Lefterov, I., & Koldamova, R. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.1001-15.2015 · Cited by 64
Kafle, P., Peller, P., Massolo, A., Hoberg, E., Leclerc, L.-M., Tomaselli, M., & Kutz, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-74358-5 · Cited by 52 · cited 1×
“For instance, a permissive environment was shown to have led to the expansion of two species of parasites in the Arctic as a consequence of climate change (Kutz et al , 2013; Kafle et al , 2020).”
Histone Lysine Methylation Dynamics Control EGFR DNA Copy-Number Amplification
Clarke, T. L., Tang, R., Chakraborty, D., Van Rechem, C., Ji, F., Mishra, S., Ma, A., Kaniskan, H. Ü., Jin, J., Lawrence, M. S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0463 · Cited by 50
Cited by
Cancer immune evasion, immunoediting and intratumour heterogeneity
Roerden, M., & Spranger, S. (2025) · Nature Reviews Immunology · doi:10.1038/s41577-024-01111-8 · Cited by 265
Metadata
- Authors
- Vendramin, R., Litchfield, K., & Swanton, C.
- Venue
- The EMBO Journal
- Published
- 2021-08-30
- Volume
- 40
- Issue
- 18
- Pages
- e108389-e108389
- ISSN
- 0261-4189 (ISSN-L)
- 1460-2075
- OpenAlex
- W3198548668
- Cited by
- 252
- References
- 47
- FWCI
- 15.18
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.